We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$180M
AUM Growth
+$35.3M
(+24%)
Cap. Flow
+$33.3M
Cap. Flow
% of AUM
18.49%
Top 10 Holdings %
Top 10 Hldgs %
21.58%
Holding
287
New
78
Increased
46
Reduced
73
Closed
55
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$4.54M |
| 2 |
Coherus Oncology
CHRS
|
+$3.29M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$2.71M |
| 4 |
Embecta
EMBC
|
+$2.55M |
| 5 |
Invesco S&P 500 Pure Value ETF
RPV
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$4.1M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$2.81M |
| 3 |
Invesco NASDAQ 100 ETF
QQQM
|
+$2.81M |
| 4 |
Innoviva
INVA
|
+$2.07M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$1.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.9% |
| 2 | Real Estate | 10.66% |
| 3 | Financials | 4.01% |
| 4 | Technology | 3.46% |
| 5 | Consumer Discretionary | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DX
26
Dynex Capital
DX
$2.87B
| $1.93M | 1.07% |
153,492
+34,902
| +29% | +$408K |
|
27
Lantheus
LNTH
$7B
| $1.93M | 1.07% |
23,000
| – | – |
|
28
Phathom Pharmaceuticals
PHAT
$873M
| $1.86M | 1.03% |
+130,000
| New | +$1.5M |
|
|
ADAM
29
Adamas Trust
ADAM
$807M
| $1.84M | 1.02% |
185,963
+13,884
| +8% | +$138K |
|
|
TSVT
30
DELISTED
2seventy bio
TSVT
| $1.82M | 1.01% |
180,000
-122,500
| -40% | -$1.3M |
|
31
MGIC Investment
MTG
$6.23B
| $1.8M | 1% |
113,900
+60,000
| +111% | +$890K |
|
32
GSK
GSK
$104B
| $1.78M | 0.99% |
50,000
-30,000
| -38% | -$1.08M |
|
33
Procept Biorobotics
PRCT
$1.09B
| $1.77M | 0.98% |
50,000
| – | – |
|
34
Intuitive Surgical
ISRG
$122B
| $1.71M | 0.95% |
5,000
| – | – |
|
35
Ironwood Pharmaceuticals
IRWD
$635M
| $1.68M | 0.93% |
+157,500
| New | +$1.69M |
|
36
ADC Therapeutics
ADCT
$172M
| $1.67M | 0.93% |
778,000
+18,000
| +2% | +$40.5K |
|
|
FOLD
37
DELISTED
Amicus Therapeutics
FOLD
| $1.66M | 0.92% |
+132,500
| New | +$1.57M |
|
|
ITCI
38
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.61M | 0.9% |
25,500
| – | – |
|
39
UroGen Pharma
URGN
$1.96B
| $1.58M | 0.88% |
+152,500
| New | +$1.68M |
|
40
Kiniksa Pharmaceuticals
KNSA
$4.92B
| $1.55M | 0.86% |
110,000
+27,500
| +33% | +$368K |
|
41
Karyopharm Therapeutics
KPTI
$216M
| $1.45M | 0.8% |
54,000
+38,000
| +238% | +$1.64M |
|
42
Fulgent Genetics
FLGT
$573M
| $1.44M | 0.8% |
39,000
-500
| -1% | -$17.4K |
|
|
PETQ
43
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $1.44M | 0.8% |
95,000
| – | – |
|
44
BioMarin Pharmaceuticals
BMRN
$11.5B
| $1.43M | 0.79% |
16,500
+11,000
| +200% | +$1.04M |
|
|
DVAX
45
DELISTED
Dynavax Technologies
DVAX
| $1.42M | 0.79% |
110,000
+2,500
| +2% | +$28.5K |
|
|
MOR
46
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $1.38M | 0.77% |
185,000
| – | – |
|
47
Accuray
ARAY
$30.8M
| $1.35M | 0.75% |
350,000
| – | – |
|
48
Ultragenyx Pharmaceutical
RARE
$2.88B
| $1.31M | 0.73% |
28,500
| – | – |
|
|
DAWN
49
DELISTED
Day One Biopharmaceuticals
DAWN
| $1.31M | 0.73% |
+110,000
| New | +$1.44M |
|
50
AGNC Investment
AGNC
$12.9B
| $1.26M | 0.7% |
124,646
+31,900
| +34% | +$310K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, AlphaCentric Advisors held 287 positions worth $180M, up 24% from $145M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $33.3M of net new capital in Q2 2023, opening 78 new positions and adding to 46 existing holdings. Its largest new stake was Embecta: 93,500 shares worth $2.02M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was iShares 1-3 Year Treasury Bond ETF, an estimated $4.1M trimmed.
- AlphaCentric Advisors's largest Q2 2023 buy was Embecta: 93,500 shares worth $2.02M.
- AlphaCentric Advisors added most to Jazz Pharmaceuticals in Q2 2023, an estimated $4.54M increase.
- AlphaCentric Advisors's biggest Q2 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $4.1M.
- AlphaCentric Advisors fully exited Invesco QQQ Trust in Q2 2023, selling an estimated $2.81M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $180M portfolio in Q2 2023.
- AlphaCentric Advisors opened 78 new positions and closed 55 in Q2 2023.
- AlphaCentric Advisors's portfolio value rose 24% quarter-over-quarter to $180M.
Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.